FDA approved Casgevy as the first CRISPR/Cas9 gene-editing therapy for sickle cell disease
Dated 8 December 2023: FDA approved Casgevy as the first CRISPR/Cas9 gene-editing therapy for sickle cell disease. In the causal graph this event strengthens the driver Gene-Editing Diffusion.
Who was responsible
Contribution type and responsibility level for each recorded actor — not sole-author shorthand.
No public contributors are listed for this fact.
What changed
Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.
- FactFDA approved Casgevy as the first CRISPR/Cas9 gene-editing therapy for sickle cell disease
- strengthensDriverGene-Editing Diffusion
provisional weight · verified
Causal path
How this event connects to drivers and indicators in the graph.
- FactFDA approved Casgevy as the first CRISPR/Cas9 gene-editing therapy for sickle cell disease
- strengthensDriverGene-Editing Diffusion
Cite this page
Factrail. (2026). FDA approved Casgevy as the first CRISPR/Cas9 gene-editing therapy for sickle cell disease. Factrail. https://factrail.ai/facts/fda-casgevy-sickle-cell-crispr-therapy-approval-december-2023
https://factrail.ai/facts/fda-casgevy-sickle-cell-crispr-therapy-approval-december-2023
Accessed 16 October 2026.
By the Factrail desk · Method: how we source and score · Last reviewed
Dispute this factNamed here, or represent someone who is? Request a right of reply.